Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
  • C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
  • C12M35/04—Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/02—Prostheses implantable into the body
  • A61F2/30—Joints
  • A61F2/30756—Cartilage endoprostheses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
  • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
  • A61L27/3612—Cartilage, synovial fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
  • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
  • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
  • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
  • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
  • A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
  • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
  • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
  • C12M21/00—Bioreactors or fermenters specially adapted for specific uses
  • C12M21/08—Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
  • C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
  • C12M25/14—Scaffolds; Matrices
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
  • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
  • C12M29/14—Pressurized fluid
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
  • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
  • C12M41/46—Means for regulation, monitoring, measurement or control, e.g. flow regulation of cellular or enzymatic activity or functionality, e.g. cell viability

Definitions

• This invention is directed to a bioreactor for generating functional cartilaginous tissue. More particularly, this invention is directed to a bioreactor for producing functional, load-bearing cartilaginous tissue from cell-seeded scaffolds subjected to applied environmental hydrostatic pressurization and scaffold deformational loading at physiologic levels.
• Articular cartilage serves as the load-bearing material of joints, with excellent friction, lubrication and wear characteristics (Mow VC, Ateshian GA, Ratcliffe A: Anatomic form and biomechanical properties of articular cartilage of the knee joint.
• Extra VC Ateshian GA
• Ratcliffe A Anatomic form and biomechanical properties of articular cartilage of the knee joint.
• Biology and biomechanics of the traumatized synovial joint the knee as a model: AAOS Symposium, ed by GAM Finerman and FR Noyes,
• Physiologic Loading-Cartilage Mechanics The loading environment of diarthrodial joints is generally well understood.
• Various classical studies have reported the magnitude of physiologic loads acting across lower and upper extremity joints (Cooney WP and Chao EYS: Biomechanical analysis of static forces in the thumb during hand functions. JBone Joint Surg 59-A:27-36, 1977; Paul JP: Forces transmitted by joints in the human body. Proc Instn Mech Engrs 181 (3J):8, 1967; Poppen NK and Walker PS: Forces at the glenohumeral joint in abduction. Clin Orthop Rel Res 135:165-70, 1978; Rydell N: Forces in the hip joint: Part (II) Intravital measurements.
• J Biomechanics 16:373-384, 1983; Brown TD and Shaw DT In vi tro contact stress distribution on the femoral condyles.
• cartilage Tissue Engineering Due to its avascular nature, cartilage exhibits a very limited capacity to regenerate and to repair. Moreover, it has been stated that the natural response of articular cartilage to injury is variable and, at best, unsatisfactory.
• tissue engineering studies aimed at the in vitro generation of cartilage replacement tissues (or implants) using chondrocyte-seeded scaffolds (e.g., Chu, C. R., Courts, R. D., Yoshioka, M., Harwood, F. L., Monosov, A. Z.
• chondrocytes are able to balance their synthetic and catabolic activities to maintain the integrity of articular cartilage in vivo.
• Buschmann and co-workers assessed the response of cell-seeded agarose disks cultured statically with time to short-term dynamic loading to assess biosynthetic activity of chondrocytes in a cell elaborated matrix and reported that cell biosynthetic activity in cultured cell-seeded agarose disks resemble that for articular cartilage.
• No studies are known to have investigated the efficacy of applied deformational loading in enhancing matrix elaboration in long-term cultures of chondrocyte-seeded scaffolds.
• It is a yet further object of the invention to develop a bioreactor that comprises means for producing tissue in desired shapes wherein the shaped tissue conforms to a body part, a prosthesis, a cosmetic implant, or a defect to be filled.
• the latter will entail loading with platens that conform to all or part of the articular surface.
• the geometry of the platens can be obtained from a database or patient-specific geometry data.
• a bioreactor is proposed for generation of load-bearing cartilaginous or fibro- cartilaginous tissue by applying hydrostatic pressure and/or deformational loading to scaffolds seeded with chondrocytes and/or other cells.
• Scaffolds may be shaped to reproduce the geometry of all or part of a load bearing articular surface or defect as acquired from a database or patient-specific geometry data.
• a scaffold is optionally attached to a substrate (e.g., hydroxyapatite) which promotes integration of this tissue construct with the underlying bone of the patient joint.
• ambient hydrostatic pressure and scaffold deformational loading can be prescribed with any desired waveform, using magnitudes which prevail in diarthrodial joints.
• the loading platen permeable or impermeable, may conform to all or part of the scaffold surfaces.
• This bioreactor maintains the sterility necessary for the production of bioengineered tissue constructs.
• This invention differs from the closest prior art in that: it provides simultaneous hydrostatic pressure and tissue deformation in a physiologic range, utilizes loading platens which can conform to a designated shape of the tissue construct, and provides for an attachment to promote integration with the underlying bone. Control of matrix strain rather than stress or load is specifically chosen to protect cells from being subjected to levels of deformation that may be detrimental to cell viability and tissue growth during applied loading.
• an apparatus useful according to the invention is a bioreactor comprising a growth chamber for housing cultured cells, a cell-seeded three- dimensional scaffold, optionally integrated with a substrate that promotes bony ingrowth for attachment to underlying bone, means for applying hydrostatic pressure and means for applying deformational loading.
• the bioreactor applies hydrostatic pressure at a level of from about 0 to about 18 MPa, with a preferred range of from about 0 to about 6 MPa.
• the bioreactor applies deformation of from about 0 to about 50% of a representative thickness of the cell-seeded scaffold, with a preferred range of 0 to about 20%.
• the scaffold in the bioreactor supports the growth of a 3-dimensional cell culture.
• the scaffold can be bioresorbable.
• the substrate is conducive to bony ingrowth.
• the invention also provides a method for producing functional cartilaginous tissue from a cell-seeded scaffold or a cell-seeded scaffold integrated with an osteoconductive and/or osteoinductive substrate.
• the method comprises the steps of (a) inoculating chondrocytes or chondroprogenitors into a scaffold or a scaffold integrated with an osteoinductive substrate; (b) placing cell-seeded scaffold or cell-seeded scaffold integrated with an osteoinductive substrate into a bioreactor; (c) filling said bioreactor with liquid growth medium; (d) applying hydrostatic pressurization and/or deformational loading to the cell-seeded scaffold or cell-seeded scaffold integrated with an osteoinductive substrate; and (e) culturing said stressed cell-seeded scaffold or cell- seeded scaffold integrated with an osteoinductive substrate for a time sufficient to produce functional cartilaginous tissue.
• the physiologically loaded cell-seeded scaffold grown according to this method displays enhanced maintenance of the chondrocyte phenotype.
• the cells produce a cartilage-like extracellular matrix.
• bioresorbable means biodegradable in cell culture or in the body of an artificial cartilage transplant recipient.
• chondrocyte means a cartilage cell. Chondrocytes are found in various types of cartilage, e.g., articular (or hyaline) cartilage, elastic cartilage, and fibrocartilage.
• substrate means a supporting structure to which the cell-seeded scaffold is anchored and which is conducive to bony ingrowth.
• “scaffold” means a three-dimensional, porous, cell culture- compatible structure, throughout which cultured mammalian cells can be seeded so as to form a 3-dimensional culture.
• “hydrostatic pressure” means a fluid-borne compressive isotropic stress (i.e., equal in all directions) acting on cultured cells.
• tissue cell means an undifferentiated cell with the potential to mature into the specialized cells characterizing a particular tissue.
• transdifferentiation means the change of a differentiated cell from one phenotype, e.g., myoblast or fibroblast, into another phenotype, e.g., a chondrocyte.
• “functional properties” means possessing the mechanical, electrical, chemical and biochemical properties of cartilaginous tissues - the properties that permit cartilage to perform and maintain its load-bearing capacity.
• Fig. 1 is a schematic representation of a bioreactor vessel according to the invention
• FIG. 2 is a schematic diagram of the operation of the bioreactor according to the invention
• Figs. 3 and 4 are each a perspective view of a bioreactor according to the invention
• Fig. 5 is a view of the interior of a bioreactor according to the invention with the top removed; and Figs. 6 to 13 reflect the steps utilized in the creation of a scaffold construct useful in the bioreactor.
• cartilaginous tissue with appropriate form and function for in vivo implantation can be created by selectively stimulating the growth and differentiated function of chondrocytes (i.e., proteoglycan and collagen synthesis) through optimization of the in vitro culture environment.
• chondrocytes i.e., proteoglycan and collagen synthesis
• Cells are inoculated into a three-dimensional scaffold, and grown in culture to form a living cartilaginous material.
• the cells may comprise chondrocytes, chondroprogenitors, with or without additional cells and/or elements described more fully herein. These cells may be fetal or adult in origin, and may be derived from convenient sources such as cartilage, skin, etc.
• tissue and/or organs can be obtained by appropriate biopsy or upon autopsy; cadaver organs may be used to provide a generous supply of cells and elements.
• umbilical cord and placenta tissue or umbilical cord blood may serve as an advantageous source of fetal-type stem cells, e.g., chondroprogenitor cells for use in the three-dimensional system of the invention.
• Cells can be inoculated into the scaffold to form a "generic" living tissue for culturing any of a variety of cells and tissues.
• a “specific” rather than “generic” system in which case cells and elements can be obtained from a particular tissue, organ, or individual.
• scaffold is to be used for purposes of transplantation or implantation in vivo, it may be preferable to obtain the cells and elements from the individual who is to receive the transplant or implant. This approach might be especially advantageous where immunological rejection of the transplant and/or graft versus host disease is likely.
• the cells Once inoculated into the 3-dimensional scaffold, the cells will proliferate in the scaffold and form the living tissue which can be used in vivo.
• the three-dimensional living tissue will sustain active proliferation of the culture for long periods of time.
• the three-dimensional scaffold is cultured in a bioreactor to produce cartilage tissue constructs possessing functional properties, under environmental conditions which are typically experienced by native cartilage tissue.
• the functional properties and rate of production of cartilage in the three-dimensional culture are significantly improved by the application of combined intermittent cyclical pressurization and deformational loading .
• the three-dimensional cultures may also be used in vitro for testing the effectiveness or cytotoxicity of pharmaceutical agents, and screening compounds.
• the bioreactor maintains an adequate supply of nutrients. Maintaining an adequate supply of nutrients to chondrocyte cells throughout a replacement cartilage tissue construct is extremely important as matrix elaborates in the scaffold.
• the three-dimensional scaffold may be of any material and/or shape that allows cells to attach to or be encapsulated in it (or can be modified to allow cells to attach to it or be encapsulated in it).
• hydrogels e.g., agarose and alginate
• nylon polyamides
• dacron polyyesters
• polystyrene polypropylene
• polyacrylates polyvinyl compounds (e.g., polyvinylchloride), polycarbonate (PVC), polytetrafluorethylene (PTFE, teflon), thermanox (TPX), nitrocellulose, cotton, polyglycolic acid (PGA), collagen (in the form of sponges, braids, or woven threads, etc.), catgut sutures, cellulose, gelatin, or other naturally occurring biodegradable materials or synthetic materials, including, for example, a variety of polyhydroxyalkanoates.
• hydrogels e.g., agarose and alginate
• nylon polyamides
• dacron polystyrene
• polypropylene polyacrylates
• polyvinyl compounds e.g., polyvinylchloride
• PVC polycarbonate
• PTFE polytetraflu
• any of these materials may be woven into a mesh, for example, to form the three-dimensional scaffold.
• Certain materials, such as nylon, polystyrene, etc. are poor substrates for cellular attachment.
• nylon matrices could be treated with 0.1M acetic acid and incubated in polylysine, PBS, and/or collagen to coat the nylon.
• Polystyrene could be similarly treated using sulfuric acid.
• non- degradable materials such as nylon, dacron, polystyrene, polyacrylates, polyvinyls, teflons, cotton, etc.
• a convenient nylon mesh which could be used in accordance with the invention is Nitex, a nylon filtration mesh having an average pore size of 210 microns and an average nylon fiber diameter of 90 microns (#3-210/36 Tetko, Inc., New York).
• biodegradable matrices such as agarose, polyglycolic acid, a polymer supplemented with a hydrogel (such as polyglycolic acid encapsulated in agarose), catgut suture material, collagen, or gelatin, for example.
• Agarose is commonly sterilized in preparation for long-term in vitro culture by autoclaving or sterile filtration.
• Cells comprising chondrocytes, chondroprogenitors, with or without other cells and elements described below, are inoculated into the scaffold.
• Cells such as chondrocytes may be derived from articular cartilage, costal cartilage, etc.
• cartilaginous tissue which can be obtained by biopsy (where appropriate) or upon autopsy.
• Fetal cells including chondroprogenitors, may be obtained from umbilical cord or placenta tissue or umbilical cord blood. Such fetal cells can be used to prepare a "generic" cartilaginous tissue.
• a "specific" cartilaginous tissue may be prepared by inoculating the three-dimensional scaffold with cells derived from a particular individual who is later to receive the tissues grown in culture in accordance with the three-dimensional system of the invention.
• Cells may also be isolated from human umbilical cords (33-44 weeks). Fresh tissues may be minced into pieces and washed with medium or snap-frozen in liquid nitrogen until further use. The umbilical tissues may be disaggregated as described above.
• the suspension can be fractionated into subpopulations from which the desired cells and/or elements can be obtained. This also may be accomplished using standard techniques for cell separation including but not limited to cloning and selection of specific cell types, selective destruction of unwanted cells (negative selection), separation based upon differential cell agglutinability in the mixed population, freeze-thaw procedures, differential adherence properties of the cells in the mixed population, filtration, conventional and zonal centrifugation, centrifugal elutriation (counter-streaming centrifugation), unit gravity separation, counter current distribution, electrophoresis and fluorescence-activated cell sorting.
• standard techniques for cell separation including but not limited to cloning and selection of specific cell types, selective destruction of unwanted cells (negative selection), separation based upon differential cell agglutinability in the mixed population, freeze-thaw procedures, differential adherence properties of the cells in the mixed population, filtration, conventional and zonal centrifugation, centrifugal elutriation (counter-streaming centrifugation), unit gravity
• chondrocytes, chondroprogenitors and other cells may, for example, be carried out as follows: fresh tissue samples are thoroughly washed and minced in Hanks balanced salt solution (HBSS) in order to remove serum. The minced tissue is incubated from 1-12 hours in a freshly prepared solution of a dissociating enzyme such as hyaluronidase and collagenase. After such incubation, the dissociated cells are suspended, pelleted by centrifugation and plated onto culture dishes. All fibroblasts will attach before other cells, therefore, appropriate cells can be selectively isolated and grown.
• HBSS Hanks balanced salt solution
• the isolated cells can then be grown to confluency, lifted from the confluent culture and inoculated onto the three-dimensional scaffold (see, Naughton et al., 1987, J. Med. 18(3&4):219-250). Inoculation of the three-dimensional scaffold with a high concentration of cells, e.g., approximately 10 6 to 5xl0 7 cells/ml, will result in the establishment of the three-dimensional tissue in shorter periods of time.
• chondrocytes or chondroprogenitors other cells may be added to form the three-dimensional scaffold required to support long term growth in culture. For example, other cells found in loose connective tissue may be inoculated onto the three- dimensional scaffold along with chondrocytes.
• Such cells include, but are not limited to, endothelial cells, pericytes, macrophages, monocytes, plasma cells, mast cells, adipocytes, etc. These cells may readily be derived from appropriate organs including umbilical cord or placenta or umbilical cord blood using methods known in the art such as those discussed above.
• the growth of cells on the three-dimensional scaffold may be further enhanced by incorporating proteins (e.g., RGDs, collagens, elastic fibers, reticular fibers) glycoproteins, glycosaminoglycans (e.g., heparin sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate, dermatan sulfate, keratin sulfate, etc.), a cellular matrix, and/or other materials into the scaffold.
• proteins e.g., RGDs, collagens, elastic fibers, reticular fibers
• glycoproteins e.g., heparin sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate, dermatan sulfate, keratin sulfate, etc.
• glycosaminoglycans e.g., heparin sulfate, chondroitin-4-sulf
• the three-dimensional scaffold After inoculation of the cells, the three-dimensional scaffold should be incubated in an appropriate nutrient medium. Many commercially available media such as DMEM, RPMI 1640, Fisher's Iscove's, McCoy's, and the like may be suitable for use.
• the culture should be "fed” periodically to remove the spent media, depopulate released cells, and add fresh media. The concentration of agonists may be adjusted during these steps.
• proline, a non-essential amino acid, and ascorbate are also included in the cultures.
• Bioreactor A schematic of one embodiment of the bioreactor useful according to the invention is shown in Fig. 1.
• the bioreactor vessel 2 comprises an upper member or vessel cap 4 and a lower member 6, secured together by bolts 8.
• each bolt 8 fits through an opening 10 in vessel cap 4, and the outer cylindrical surface 12 of each bolt 8 has threads that engage mating threads 14 in each tapped hole 16. Sealing is effected by an O-ring 18 in a groove 20.
• an agarose template 24 has indentations or wells 26 that contain cell-seeded agarose disks 28. These wells prevent shifting of the disks during loading or transport.
• a compression loading platen 30 is rigidly attached to a actuator rod 32 that extends through opening 33 in vessel cap 4 to a displacement actuator device (not shown). O-rings 34 in grooves 36 provide sealing around actuator rod 32.
• a lateral surface 40 of lower member 6 has removably engaged thereto a hydraulic pressure assembly 42 having a lumen or piston chamber 44.
• a hydraulic pressure control rod or piston 46 extends within lumen 44, the proximal end of pressure control rod 46 being operatively connected to a displacement actuator device (not shown).
• a displacement actuator device not shown.
• Pressure assembly 42 comprises an end member 52 through which pressure control rod 46 passes.
• O-rings 54 in grooves 56 provide sealing.
• Another portion of lateral surface 40 of lower chamber 6 comprises a pressure transducer 60 for measurement of the hydrostatic pressure within chamber 22.
• Transducer 60 is operatively, e.g., mechanically or electrically, connected to a pressure read-out (not shown).
• Fig. 2 represents a schematic of the operation of a chamber of Fig. 1 according to the invention.
• Air from air pressure source 70 passes through an air filter 72 into a valve manifold 74, which is operatively connected to a pulse train generator 76.
• Pressurized air from valve manifold 74 is directed to pressure regulation controls 78,80,82,84 in a displacement actuator air piston cylinder 86 connected to actuator rod 32 and a displacement actuator air piston cylinder 88 connected to pressure control rod 46.
• the latter air piston provides the force necessary to displace the pressure control rod 46 by utilizing the mechanical advantage of converting a low pressure on a large piston area into a high pressure on a small piston area.
• Actuator rod 32 and pressure control rod 46 each engage external loose bellows 47, 49, which provide a separation of the internal sterile environment of the bioreactor from the outside.
• Fig. 3 is a perspective view of one embodiment of the bioreactor 2 with a compressive strain (deformational loading) air cylinder 86 and a hydrostatic pressure air cylinder assembly 88.
• a closer view of bioreactor 2 is provided in Fig. 4, which clearly displays compressive strain air cylinder assembly 86 and displacement actuator rod 32 that collectively form the displacement actuator device.
• Fig. 5 is a view of the interior chamber 22 of bioreactor 2, which is the interior of lower member 6 in which the vessel cap 4 (not shown) is secured with circular O-ring 18 and threaded screws into threaded openings 10,14,16.
• a partial view of piston chamber lumen 44 of hydraulic pressure assembly 42 for which a hydraulic pressure control rod or piston is extended within to increase the pressure in chamber 22 can be seen.
• a pressure transducer 60 is used to monitor pressure development within chamber 22. Chondrocyte-seeded agarose disks 28 have been positioned within chamber 22. During normal functioning of the bioreactor, chamber 22 would be completely filled with cell culture medium supplemented with appropriate factors (such as nutrients, growth factors, buffers, etc.).
• a typical loading regimen for the cell-seeded agarose disks consists of applying cyclical hydrostatic pressure with an amplitude of 2 MPa and/or deformational loading with an amplitude of 10%, at a frequency of 1 Hz.
• the time-course of dynamic loading consists of three consecutive 1-hour-on, 1-hour-off cycles per day, for 5 days per week, for 8 weeks.
• the objective of the above example is to provide a physiologic loading environment for the chondrocyte-seeded agarose disks to promote growth of functional hyaline cartilage.
• One advantage of agarose over other scaffold materials is that it can sustain mechanical loading at physiologic strains without permanent deformation. Together the biocompatibility and mechanical properties of agarose make it possible to apply load to chondrocyte-seeded agarose cultures immediately upon seeding of cells. This allows for assessment of the effects of mechanical loads during the initial stages of tissue development.
• the cell-seeded agarose disk is loaded between impermeable smooth loading platens and is free to expand laterally (i.e., in the radial direction).
• the interstitial fluid hydrostatic pressure and the scaffold compressive strain along the axial direction of the cylindrical disk are uniform through the thickness of the sample, and there is no fluid flow relative to the solid matrix along the axial loading direction.
• the hydrostatic pressure and tensile radial and circumferential strains are uniform from the center almost to the periphery of the sample, with pressure, strain and fluid flow gradients occurring only in a narrow region near the sample edges.
• unconfmed compression produces more uniform mechanical signals throughout a cylindrical sample than that of confined compression, which is more suitable for tissue engineering purposes.
• uniformity of the interstitial fluid pressure through the depth of the sample is more physiologic; unconfmed compression produces both compressive strains (along the axial direction) and tensile strains (along the radial and circumferential directions), which also represents a more physiologic loading environment than confined compression, as suggested by analyses of contacting cartilage layers.
• unconfmed compression can produce tissue strains with negligible change in tissue volume (since the disk can expand laterally when compressed axially), while confined compression is always accompanied by loss of tissue volume due to water efflux; in vivo measurements of cartilage volumetric changes have been shown to be small (6%) even following strenuous loading.
• the loading configuration adopted for the above example is that of unconfmed compression.
• the loading rate of 1 Hz suggested above is motivated by the need to produce physiological loading conditions. It is reasonable to expect that human joints can be comfortably subjected to activities of moderate loading at a nearly cyclical rate of 1 Hz, continuously for 30 minutes or longer (e.g., going on a walk - for loading of the lower extremities - or writing with pen on paper - for loading of the finger and thumb joints).
• Cylindrical disks consisting of chondrocytes suspended in agarose can be prepared as follows. Articular cartilage is harvested from the carpo-metacarpal joint of freshly killed 4-6 month old bovine calves obtained from a local abattoir and rinsed in Dulbecco's Modified Essential Medium (DMEM) supplemented with 10% FBS, amino acids (0.5X minimal essential amino acids, IX non-essential amino acids), buffering agents (10 mM Hepes, 10 mM sodium bicarbonate, 10 mM TES, 10 mM BES), and antibiotics (100 U/ml penicillin, 100 ⁇ g/ml streptomycin).
• DMEM Dulbecco's Modified Essential Medium
• the cartilage chunks are digested with 50 mg of bovine testicular hyaluronidase type I-S (Sigma Chemical Company, St. Louis, MO) in 100 ml of DMEM for 30 minutes at 37° C. After removal of the hyaluronidase solution, the cartilage specimens are digested at 37° C overnight with 50 mg of clostridial collagenase type II (Sigma) in 100 ml of DMEM. The cell suspension will then be sedimented in a benchtop clinical centrifuge at 4° C for 5 minutes. After rinsing the pellets, the cells are finally resuspended in 10 ml of DMEM, and viable cells are counted using a hemacytometer and trypan blue exclusion.
• chondrocyte/agarose constructs For the preparation of chondrocyte/agarose constructs, one volume of chondrocyte suspension (2 x 10 7 cells/ml) is mixed with an equal volume of 4% molten Type VII agarose (Sigma) in Hank's balanced salt solution (HBSS) at 37° C to yield a final cell concentration of 1 x 10 7 cells/ml in 2% agarose. After mixing, the chondrocyte/agarose mixture is poured into sterile 16 cm x 20 cm molds consisting of two glass plates separated by 3-mm spacers. The molds areincubated at 4° C for 10 min to allow the agarose to gel. Cylindrical disks of 10-mm diameter are then cored from the chondrocyte/agarose slabs with a 10-mm trephine, rinsed twice in DMEM and cultured as described below.
• HBSS Hank's balanced salt solution
• Chondrocyte/agarose disks are maintained in culture for up to 6 weeks (42 days), with daily change of growth medium.
• the growth medium consists of DMEM supplemented as indicated above.
• the medium is also supplemented with 50 ⁇ g ascorbate/ml.
• Disks are grown in the bioreactor which is placed in an incubator, preferably at 37°C. As loading is carried out every day, cell-laden disks are left in the vessel base for overnight culture. Fresh media is introduced into the bioreactor on a daily basis using access ports.
• the anatomic shape of the loading platen and scaffold can be based upon obtaining imaging data (e.g., stereophotogram- metry, magnetic resonance imaging, computed tomography) of a patient's healthy contralateral joint surfaces and optionally modifying the imaged data of the patient's healthy contralateral joint surfaces to provide a more functional surface topography.
• imaging data e.g., stereophotogram- metry, magnetic resonance imaging, computed tomography
• the anatomic shape of the loading platen and scaffold can be based on a database of a plurality of joint surface archetypes acquired through measurement of a plurality of joint surfaces, said plurality of joint surface archetypes being cross- referenced by parameters including dimensions of bone associated with joint surface, the weight of a person from whom the measurement is being taken, the sex of the person from whom the measurement is being taken, the race of the person from whom the measurement is being taken, and the height of the person from whom the measurement is being taken, input means for receiving a plurality of parameters exhibited by the patient, a microprocessor connected to said memory means for selecting one of said plurality of joint surface archetypes whose parameters most closely resemble a corresponding plurality of parameters exhibited by the patient, by said microprocessor for fabricating the joint prosthesis to resemble the selected articular joint surface archetype.
• the imaged data of the articular topography can then be converted into a three-dimensional surface contour using commercially available computer-aided design software. These contours can be employed to create a solid computer model from which physical molds can be generated using a technique for three-dimensional fabrication (such as computerized numerical control machine tools, rapid prototype machine, stereolithography). These molds then serve to create a scaffold having the articular topography of the desired imaged data as well as loading platens that mate congruently with the scaffold surface
• Figs. 6 to 13 depict the creation of an agarose scaffold construct having the articular layer topography of a human patella that has been generated using a mold fabricated using rapid prototype machining.
• a computer-aided design drawing of the mold and scaffold construct are shown in Fig. 6, whereas a rapid prototype of this mold containing the agarose scaffold construct 96 is shown in Fig. 7.
• Two halves of the mold (each having the specified articular topography of the articular surface 90 and subchondral bone surface 94 are separated by a spacer ring 92 that defines the thickness of the scaffold construct and serves to create an enclosed volume having the shape of the desired construct.
• melted 2% agarose containing chondrocytes or other progenitor cells has been poured into the mold and permitted to cool, resulting with the creation of a three-dimensional agarose scaffold construct having the surface topography of the desired articular layer (Fig. 7, 96).
• Fig. 8 depicts a computer-aided design drawing of the scaffold construct 96 when it has been seated between two congruent loading platens 98,100
• Fig. 9 depicts the scaffold construct 96 when it has been seated between two congruent loading platens 98,100 constructed of ABS plastic from the rapid prototype machine.
• Fig. 10 depicts the agarose construct seated on the lower platen 98 conforming to the subchondral bone surface, with the top platen 100, conforming to the articular surface, removed and in the background.
• Fig. 11 depicts the lower loading platen 98
• Fig. 12 depicts the three dimensional agarose construct 96 created from the mold 90,92,94
• Fig. 13 depicts the upper loading platen 100.
• the preferred embodiment for the mold and loading platen material would be one that is sterilizable, rigid and machineable (such as stainless steel, polysulfone).
• the loading platen reproducing the subchondral bone surface of the anatomic articular layer is replaced with a porous osteoconductive and/or osteoinductive anatomically shaped substrate which similarly reproduces the subchondral bone surface.
• a solution such as melted 2% agarose, containing chondrocyte or projenitor cells is then poured over and into the porous substrate.
• This anatomically shaped substrate optionally modified, will serve subsequently as a part of the scaffold construct to promote bony integration in vivo. Bone cells or bone progenitor cells can be seeded into or onto the bony substrate.
• the molds described herein are used to create scaffold constructs from a variety of biomaterials, having the anatomic shape of a desired articular layer surface, which are then seeded with chondrocytes or progenitor cells and then subsequently subjected to physiologic loading using the bioreactor with loading platens that are conforming to the shape of the scaffold construct.
• the aforementioned scaffold construct can be attached (such as with a biocompatible adhesive, suturing etc.) to a bony substrate (osteoconductive and/or osteoinductive) that forms the loading platen facing the subchondral side of the anatomic articular layer.
• This loading platen optionally modified, will serve subsequently as a part of the scaffold construct to promote bony integration in vivo.
• Bone cells or bone cell progenitor cells can be seeded into or onto the bony substrate.

Priority Applications (1)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22694063

Family Applications (1)

Country Status (2)

Cited By (41)

Citations (2)

• 2001
  • 2001-03-12 WO PCT/US2001/007815 patent/WO2001068800A1/en active Application Filing
  • 2001-03-12 AU AU2001243581A patent/AU2001243581A1/en not_active Abandoned

Patent Citations (2)

Also Published As

Similar Documents

Legal Events